1. Screening should not be carried out in asymptomatic women who have no risk factors. 2. There is no evidence that screening of high-risk populations reduces mortality.
Diagnosis ! 1. The diagnosis of endometrial cancer and its precursors must be confirmed by histological sampling. 2. Every post-menopausal bleeding must be investigated irrespective of endometrial thickness on ultrasound.
Atypical bleeding in perimenopausal women
should be investigated histologically.
4. Only bleeding requires histological investigation in women receiving tamoxifen. 5. There are currently no imaging methods which could replace surgical staging in endometrial cancer. Magnetic resonance imaging should be done to plan radiotherapy for women whose cancer is inoperable due to comorbidities. 6. Histological classification of endometrial cancers and their precursors follows the WHO criteria. 7. Any report of histopathological findings for endometrial cancer must include: tumor type, grading, depth of invasion into the myometrium, invasion of stromal connective tissue of the cervix, lymph node involvement if applicable, R classification, lymphatic and vascular metastasis, and nerve sheath invasion.
Patient Information ! 1. The information provided to patients (print or internet media) must be compiled in accordance with the quality requirements of the Guideline on Information Provided to Women to support every patient in her autonomous decision for or against medical treatment by communicating the risks involved in a comprehensible form (information should list incidence rather than relative percentage TX  Primary tumor cannot be assessed  T0  No evidence of primary tumor  T1  I 1  Tumor confined to corpus uteri  T1a  IA 1  Tumor limited to endometrium or invades less than one half of the myometrium  T1b  IB  Tumor invades one half or more of the myometrium  T2 II Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus T3 and/or N1 III Local and/or regional extension or metastasis as described below: T3a IIIA Tumor involves serosa or adnexa (direct extension or metastasis) T3b IIIB Vaginal involvement or parametrial involvement (direct extension or metastasis) N1 IIIC Metastasis to pelvic and/or para-aortic lymph nodes 2 IIIC1
TNM categories FIGO stages Definitions
Metastasis to pelvic lymph nodes IIIC2
Metastasis to para-aortic lymph nodes T4 IVA Tumor invades bladder mucosa and/or bowel mucosa 3 M1 IVB Distant metastasis (excludes metastasis to the vagina, pelvic serosa or adnexa; includes metastasis to inguinal and intra-abdominal lymph nodes other than para-aortic and/or pelvic lymph nodes) 7. Randomized studies found a significant reduction of locoregional recurrence in patients with stage I and II disease after adjuvant radiation therapy, but this had no significant impact on overall survival. The available data for advanced disease is insufficient to permit any recommendations to be made.
Systemic adjuvant therapy
1. Patients should not receive adjuvant endocrine therapy with gestagens. 2. Patients with stage IB G3, II and III disease and all patients with serous or clear cell endometrial cancer should receive chemotherapy sequential to radiation therapy (brachytherapy and/or teletherapy). The most studied chemotherapy regimen consists of a combination of platinum-based chemotherapy plus paclitaxel. 3. Patients with stage IVA can undergo chemotherapy and/or sequential radiation therapy after surgery. The most studied chemotherapy regimen consists of a combination of platinumbased chemotherapy plus paclitaxel. However, the optimal combination and sequence have not yet been defined for this combination.
Palliative systemic therapy 1. Endocrine therapy with gestagens should be offered to patients with estrogen and/or progesterone receptor-positive cancer who have inoperable recurrence or metastasis not amenable to radiation therapy if metastases are not acutely lifethreatening. 2. Palliative chemotherapy can be offered to patients who present with disease progression despite endocrine therapy and to patients with receptor-negative tumors or acutely life-threatening tumors. Effective substances include anthracyclines, platinum derivatives and taxanes. 3. Combination chemotherapy regimens have better response rates and progression-free survival rates compared to monotherapies, but the benefits in terms of overall survival are only marginal. The combination of carboplatin/paclitaxel should be used if the patient can sufficiently tolerate the regimen as the efficacy of this regimen is the same as for the combination of adriamycin/cisplatin/paclitaxel but toxicity is lower.
